▶ 調査レポート

世界の遺伝性血管性浮腫(HAE)市場 2021:企業別、地域別、種類・用途別

• 英文タイトル:Global Hereditary Angioedema Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026

GlobalInfoResearchが調査・発行した産業分析レポートです。世界の遺伝性血管性浮腫(HAE)市場 2021:企業別、地域別、種類・用途別 / Global Hereditary Angioedema Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026 / GIR-111D11544資料のイメージです。• レポートコード:GIR-111D11544
• 出版社/出版日:GlobalInfoResearch / 2021年10月30日
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、88ページ
• 納品方法:Eメール(納期:2~3日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥515,040 (USD3,480)▷ お問い合わせ
  Multi User¥772,560 (USD5,220)▷ お問い合わせ
  Corporate User¥1,030,080 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査資料では、遺伝性血管性浮腫(HAE)のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。遺伝性血管性浮腫(HAE)の種類別市場規模(C1エステラーゼ阻害剤、カリクレイン阻害剤、選択的ブラジキニンB2受容体拮抗薬)、用途別市場規模(小売薬局、病院薬局、オンライン薬局)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・遺伝性血管性浮腫(HAE)の市場概要
・企業情報(企業概要、製品概要、販売量、価格、売上):Pharming Group NV、Takeda、CSL Limited、iBio Inc.、BioCryst Pharmaceuticals, Inc.、Ionis Pharmaceuticals, Inc.
・企業別市場シェア
・地域別市場分析2016年-2026年
・種類別分析2016年-2026年:C1エステラーゼ阻害剤、カリクレイン阻害剤、選択的ブラジキニンB2受容体拮抗薬
・用途別分析2016年-2026年:小売薬局、病院薬局、オンライン薬局
・遺伝性血管性浮腫(HAE)の北米市場規模2016年-2026年:アメリカ、カナダ、メキシコ
・遺伝性血管性浮腫(HAE)のヨーロッパ市場規模2016年-2026年:ドイツ、イギリス、フランス、ロシア、イタリア
・遺伝性血管性浮腫(HAE)のアジア市場規模2016年-2026年:中国、日本、韓国、インド、東南アジア、オーストラリア
・遺伝性血管性浮腫(HAE)の南米市場規模2016年-2026年:ブラジル、アルゼンチン
・遺伝性血管性浮腫(HAE)の中東・アフリカ市場規模2016年-2026年:サウジアラビア、トルコ、エジプト、南アフリカ
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Hereditary Angioedema market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Hereditary Angioedema size is estimated to be xx million in 2021 from USD 1704.7 million in 2020, with a change of XX% between 2020 and 2021. The global Hereditary Angioedema market size is expected to grow at a CAGR of 7.0% for the next five years.

Market segmentation
Hereditary Angioedema market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
C1 Esterase Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist

Market segment by Application can be divided into
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

The key market players for global Hereditary Angioedema market are listed below:
Pharming Group NV
Takeda
CSL Limited
iBio Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.

Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Hereditary Angioedema product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Hereditary Angioedema, with price, sales, revenue and global market share of Hereditary Angioedema from 2019 to 2021.
Chapter 3, the Hereditary Angioedema competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Hereditary Angioedema breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Hereditary Angioedema market forecast, by regions, type and distribution channel, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Hereditary Angioedema sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

1 Market Overview
1.1 Hereditary Angioedema Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Hereditary Angioedema Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 C1 Esterase Inhibitor
1.2.3 Kallikrein Inhibitor
1.2.4 Selective Bradykinin B2 Receptor Antagonist
1.3 Market Analysis by Distribution Channel
1.3.1 Overview: Global Hereditary Angioedema Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Retail Pharmacies
1.3.3 Hospital Pharmacies
1.3.4 Online Pharmacies
1.4 Global Hereditary Angioedema Market Size & Forecast
1.4.1 Global Hereditary Angioedema Sales in Value (2016-2026))
1.4.2 Global Hereditary Angioedema Sales in Volume (2016-2026)
1.4.3 Global Hereditary Angioedema Price by Type (2016-2026) & (USD/Kg)
1.5 Global Hereditary Angioedema Production Capacity Analysis
1.5.1 Global Hereditary Angioedema Total Production Capacity (2016-2026)
1.5.2 Global Hereditary Angioedema Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Hereditary Angioedema Market Drivers
1.6.2 Hereditary Angioedema Market Restraints
1.6.3 Hereditary Angioedema Trends Analysis
2 Manufacturers Profiles
2.1 Pharming Group NV
2.1.1 Pharming Group NV Details
2.1.2 Pharming Group NV Major Business
2.1.3 Pharming Group NV Hereditary Angioedema Product and Services
2.1.4 Pharming Group NV Hereditary Angioedema Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Takeda
2.2.1 Takeda Details
2.2.2 Takeda Major Business
2.2.3 Takeda Hereditary Angioedema Product and Services
2.2.4 Takeda Hereditary Angioedema Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 CSL Limited
2.3.1 CSL Limited Details
2.3.2 CSL Limited Major Business
2.3.3 CSL Limited Hereditary Angioedema Product and Services
2.3.4 CSL Limited Hereditary Angioedema Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 iBio Inc.
2.4.1 iBio Inc. Details
2.4.2 iBio Inc. Major Business
2.4.3 iBio Inc. Hereditary Angioedema Product and Services
2.4.4 iBio Inc. Hereditary Angioedema Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 BioCryst Pharmaceuticals, Inc.
2.5.1 BioCryst Pharmaceuticals, Inc. Details
2.5.2 BioCryst Pharmaceuticals, Inc. Major Business
2.5.3 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Product and Services
2.5.4 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Ionis Pharmaceuticals, Inc.
2.6.1 Ionis Pharmaceuticals, Inc. Details
2.6.2 Ionis Pharmaceuticals, Inc. Major Business
2.6.3 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Product and Services
2.6.4 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Hereditary Angioedema Sales by Manufacturer
3.1 Global Hereditary Angioedema Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Hereditary Angioedema Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Hereditary Angioedema
3.4 Market Concentration Rate
3.4.1 Top 3 Hereditary Angioedema Manufacturer Market Share
3.4.2 Top 6 Hereditary Angioedema Manufacturer Market Share
3.5 Global Hereditary Angioedema Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Hereditary Angioedema Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Hereditary Angioedema Market Size by Region
4.1.1 Global Hereditary Angioedema Sales in Volume by Region (2016-2026)
4.1.2 Global Hereditary Angioedema Revenue by Region (2016-2026)
4.2 North America Hereditary Angioedema Revenue (2016-2026)
4.3 Europe Hereditary Angioedema Revenue (2016-2026)
4.4 Asia-Pacific Hereditary Angioedema Revenue (2016-2026)
4.5 South America Hereditary Angioedema Revenue (2016-2026)
4.6 Middle East and Africa Hereditary Angioedema Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Hereditary Angioedema Sales in Volume by Type (2016-2026)
5.2 Global Hereditary Angioedema Revenue by Type (2016-2026)
5.3 Global Hereditary Angioedema Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Hereditary Angioedema Sales in Volume by Application (2016-2026)
6.2 Global Hereditary Angioedema Revenue by Application (2016-2026)
6.3 Global Hereditary Angioedema Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Hereditary Angioedema Sales by Type (2016-2026)
7.2 North America Hereditary Angioedema Sales by Application (2016-2026)
7.3 North America Hereditary Angioedema Market Size by Country
7.3.1 North America Hereditary Angioedema Sales in Volume by Country (2016-2026)
7.3.2 North America Hereditary Angioedema Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Hereditary Angioedema Sales by Type (2016-2026)
8.2 Europe Hereditary Angioedema Sales by Application (2016-2026)
8.3 Europe Hereditary Angioedema Market Size by Country
8.3.1 Europe Hereditary Angioedema Sales in Volume by Country (2016-2026)
8.3.2 Europe Hereditary Angioedema Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Hereditary Angioedema Sales by Type (2016-2026)
9.2 Asia-Pacific Hereditary Angioedema Sales by Application (2016-2026)
9.3 Asia-Pacific Hereditary Angioedema Market Size by Region
9.3.1 Asia-Pacific Hereditary Angioedema Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Hereditary Angioedema Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Hereditary Angioedema Sales by Type (2016-2026)
10.2 South America Hereditary Angioedema Sales by Application (2016-2026)
10.3 South America Hereditary Angioedema Market Size by Country
10.3.1 South America Hereditary Angioedema Sales in Volume by Country (2016-2026)
10.3.2 South America Hereditary Angioedema Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Hereditary Angioedema Sales by Type (2016-2026)
11.2 Middle East & Africa Hereditary Angioedema Sales by Application (2016-2026)
11.3 Middle East & Africa Hereditary Angioedema Market Size by Country
11.3.1 Middle East & Africa Hereditary Angioedema Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Hereditary Angioedema Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Hereditary Angioedema Typical Distributors
12.3 Hereditary Angioedema Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

List of Tables
Table 1. Global Hereditary Angioedema Revenue by Type, (USD Million), 2021-2026
Table 2. Global Hereditary Angioedema Revenue by Application, (USD Million), 2021-2026
Table 3. Pharming Group NV Basic Information, Manufacturing Base and Competitors
Table 4. Pharming Group NV Major Business
Table 5. Pharming Group NV Hereditary Angioedema Product and Services
Table 6. Pharming Group NV Hereditary Angioedema Sales (MT), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Takeda Basic Information, Manufacturing Base and Competitors
Table 8. Takeda Major Business
Table 9. Takeda Hereditary Angioedema Product and Services
Table 10. Takeda Hereditary Angioedema Sales (MT), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. CSL Limited Basic Information, Manufacturing Base and Competitors
Table 12. CSL Limited Major Business
Table 13. CSL Limited Hereditary Angioedema Product and Services
Table 14. CSL Limited Hereditary Angioedema Sales (MT), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. iBio Inc. Basic Information, Manufacturing Base and Competitors
Table 16. iBio Inc. Major Business
Table 17. iBio Inc. Hereditary Angioedema Product and Services
Table 18. iBio Inc. Hereditary Angioedema Sales (MT), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. BioCryst Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 20. BioCryst Pharmaceuticals, Inc. Major Business
Table 21. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Product and Services
Table 22. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Sales (MT), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Ionis Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 24. Ionis Pharmaceuticals, Inc. Major Business
Table 25. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Product and Services
Table 26. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Sales (MT), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Global Hereditary Angioedema Sales by Manufacturer (2019-2021e) & (MT)
Table 28. Global Hereditary Angioedema Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 29. Market Position of Manufacturers in Hereditary Angioedema, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 30. Global Hereditary Angioedema Production Capacity by Company, (MT): 2020 VS 2021
Table 31. Head Office and Hereditary Angioedema Production Site of Key Manufacturer
Table 32. Hereditary Angioedema New Entrant and Capacity Expansion Plans
Table 33. Hereditary Angioedema Mergers & Acquisitions in the Past Five Years
Table 34. Global Hereditary Angioedema Sales by Region (2016-2021e) & (MT)
Table 35. Global Hereditary Angioedema Sales by Region (2021-2026) & (MT)
Table 36. Global Hereditary Angioedema Revenue by Region (2016-2021e) & (USD Million)
Table 37. Global Hereditary Angioedema Revenue by Region (2021-2026) & (USD Million)
Table 38. Global Hereditary Angioedema Sales by Type (2016-2021e) & (MT)
Table 39. Global Hereditary Angioedema Sales by Type (2021-2026) & (MT)
Table 40. Global Hereditary Angioedema Revenue by Type (2016-2021e) & (USD Million)
Table 41. Global Hereditary Angioedema Revenue by Type (2021-2026) & (USD Million)
Table 42. Global Hereditary Angioedema Price by Type (2016-2021e) & (USD/Kg)
Table 43. Global Hereditary Angioedema Price by Type (2021-2026) & (USD/Kg)
Table 44. Global Hereditary Angioedema Sales by Application (2016-2021e) & (MT)
Table 45. Global Hereditary Angioedema Sales by Application (2021-2026) & (MT)
Table 46. Global Hereditary Angioedema Revenue by Application (2016-2021e) & (USD Million)
Table 47. Global Hereditary Angioedema Revenue by Application (2021-2026) & (USD Million)
Table 48. Global Hereditary Angioedema Price by Application (2016-2021e) & (USD/Kg)
Table 49. Global Hereditary Angioedema Price by Application (2021-2026) & (USD/Kg)
Table 50. North America Hereditary Angioedema Sales by Country (2016-2021e) & (MT)
Table 51. North America Hereditary Angioedema Sales by Country (2021-2026) & (MT)
Table 52. North America Hereditary Angioedema Revenue by Country (2016-2021e) & (USD Million)
Table 53. North America Hereditary Angioedema Revenue by Country (2021-2026) & (USD Million)
Table 54. North America Hereditary Angioedema Sales by Type (2016-2021e) & (MT)
Table 55. North America Hereditary Angioedema Sales by Type (2021-2026) & (MT)
Table 56. North America Hereditary Angioedema Sales by Application (2016-2021e) & (MT)
Table 57. North America Hereditary Angioedema Sales by Application (2021-2026) & (MT)
Table 58. Europe Hereditary Angioedema Sales by Country (2016-2021e) & (MT)
Table 59. Europe Hereditary Angioedema Sales by Country (2021-2026) & (MT)
Table 60. Europe Hereditary Angioedema Revenue by Country (2016-2021e) & (USD Million)
Table 61. Europe Hereditary Angioedema Revenue by Country (2021-2026) & (USD Million)
Table 62. Europe Hereditary Angioedema Sales by Type (2016-2021e) & (MT)
Table 63. Europe Hereditary Angioedema Sales by Type (2021-2026) & (MT)
Table 64. Europe Hereditary Angioedema Sales by Application (2016-2021e) & (MT)
Table 65. Europe Hereditary Angioedema Sales by Application (2021-2026) & (MT)
Table 66. Asia-Pacific Hereditary Angioedema Sales by Region (2016-2021e) & (MT)
Table 67. Asia-Pacific Hereditary Angioedema Sales by Region (2021-2026) & (MT)
Table 68. Asia-Pacific Hereditary Angioedema Revenue by Region (2016-2021e) & (USD Million)
Table 69. Asia-Pacific Hereditary Angioedema Revenue by Region (2021-2026) & (USD Million)
Table 70. Asia-Pacific Hereditary Angioedema Sales by Type (2016-2021e) & (MT)
Table 71. Asia-Pacific Hereditary Angioedema Sales by Type (2021-2026) & (MT)
Table 72. Asia-Pacific Hereditary Angioedema Sales by Application (2016-2021e) & (MT)
Table 73. Asia-Pacific Hereditary Angioedema Sales by Application (2021-2026) & (MT)
Table 74. South America Hereditary Angioedema Sales by Country (2016-2021e) & (MT)
Table 75. South America Hereditary Angioedema Sales by Country (2021-2026) & (MT)
Table 76. South America Hereditary Angioedema Revenue by Country (2016-2021e) & (USD Million)
Table 77. South America Hereditary Angioedema Revenue by Country (2021-2026) & (USD Million)
Table 78. South America Hereditary Angioedema Sales by Type (2016-2021e) & (MT)
Table 79. South America Hereditary Angioedema Sales by Type (2021-2026) & (MT)
Table 80. South America Hereditary Angioedema Sales by Application (2016-2021e) & (MT)
Table 81. South America Hereditary Angioedema Sales by Application (2021-2026) & (MT)
Table 82. Middle East & Africa Hereditary Angioedema Sales by Country (2016-2021e) & (MT)
Table 83. Middle East & Africa Hereditary Angioedema Sales by Country (2021-2026) & (MT)
Table 84. Middle East & Africa Hereditary Angioedema Revenue by Country (2016-2021e) & (USD Million)
Table 85. Middle East & Africa Hereditary Angioedema Revenue by Country (2021-2026) & (USD Million)
Table 86. Middle East & Africa Hereditary Angioedema Sales by Type (2016-2021e) & (MT)
Table 87. Middle East & Africa Hereditary Angioedema Sales by Type (2021-2026) & (MT)
Table 88. Middle East & Africa Hereditary Angioedema Sales by Application (2016-2021e) & (MT)
Table 89. Middle East & Africa Hereditary Angioedema Sales by Application (2021-2026) & (MT)
Table 90. Direct Channel Pros & Cons
Table 91. Indirect Channel Pros & Cons
Table 92. Hereditary Angioedema Typical Distributors
Table 93. Hereditary Angioedema Typical Customers
List of Figures
Figure 1. Hereditary Angioedema Picture
Figure 2. Global Hereditary Angioedema Sales Market Share by Type in 2020
Figure 3. C1 Esterase Inhibitor
Figure 4. Kallikrein Inhibitor
Figure 5. Selective Bradykinin B2 Receptor Antagonist
Figure 6. Global Hereditary Angioedema Sales Market Share by Application in 2020
Figure 7. Retail Pharmacies
Figure 8. Hospital Pharmacies
Figure 9. Online Pharmacies
Figure 10. Global Hereditary Angioedema Market Size, (USD Million) & (MT): 2020 VS 2021 VS 2026
Figure 11. Global Hereditary Angioedema Market Size and Forecast (2016-2026) & (USD Million)
Figure 12. Global Hereditary Angioedema Sales (2016-2026) & (MT)
Figure 13. Global Hereditary Angioedema Price by Type (2016-2026) & (USD/Kg)
Figure 14. Global Hereditary Angioedema Production Capacity (2016-2026) & (MT)
Figure 15. Global Hereditary Angioedema Production Capacity by Geographic Region: 2020 VS 2021
Figure 16. Hereditary Angioedema Market Drivers
Figure 17. Hereditary Angioedema Market Restraints
Figure 18. Hereditary Angioedema Market Trends
Figure 19. Global Hereditary Angioedema Sales Market Share by Manufacturer in 2020
Figure 20. Global Hereditary Angioedema Revenue Market Share by Manufacturer in 2020
Figure 21. Hereditary Angioedema Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 22. Top 3 Hereditary Angioedema Manufacturer (Revenue) Market Share in 2020
Figure 23. Top 6 Hereditary Angioedema Manufacturer (Revenue) Market Share in 2020
Figure 24. Global Hereditary Angioedema Sales Market Share by Region (2016-2026)
Figure 25. Global Hereditary Angioedema Revenue Market Share by Region (2016-2026)
Figure 26. North America Hereditary Angioedema Revenue (2016-2026) & (USD Million)
Figure 27. Europe Hereditary Angioedema Revenue (2016-2026) & (USD Million)
Figure 28. Asia-Pacific Hereditary Angioedema Revenue (2016-2026) & (USD Million)
Figure 29. South America Hereditary Angioedema Revenue (2016-2026) & (USD Million)
Figure 30. Middle East & Africa Hereditary Angioedema Revenue (2016-2026) & (USD Million)
Figure 31. Global Hereditary Angioedema Sales Market Share by Type (2016-2026)
Figure 32. Global Hereditary Angioedema Revenue Market Share by Type (2016-2026)
Figure 33. Global Hereditary Angioedema Price by Type (2016-2026) & (USD/Kg)
Figure 34. Global Hereditary Angioedema Sales Market Share by Application (2016-2026)
Figure 35. Global Hereditary Angioedema Revenue Market Share by Application (2016-2026)
Figure 36. Global Hereditary Angioedema Price by Application (2016-2026) & (USD/Kg)
Figure 37. North America Hereditary Angioedema Sales Market Share by Type (2016-2026)
Figure 38. North America Hereditary Angioedema Sales Market Share by Application (2016-2026)
Figure 39. North America Hereditary Angioedema Sales Market Share by Country (2016-2026)
Figure 40. North America Hereditary Angioedema Revenue Market Share by Country (2016-2026)
Figure 41. United States Hereditary Angioedema Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 42. Canada Hereditary Angioedema Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Mexico Hereditary Angioedema Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Europe Hereditary Angioedema Sales Market Share by Type (2016-2026)
Figure 45. Europe Hereditary Angioedema Sales Market Share by Application (2016-2026)
Figure 46. Europe Hereditary Angioedema Sales Market Share by Country (2016-2026)
Figure 47. Europe Hereditary Angioedema Revenue Market Share by Country (2016-2026)
Figure 48. Germany Hereditary Angioedema Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. France Hereditary Angioedema Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. United Kingdom Hereditary Angioedema Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Russia Hereditary Angioedema Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Italy Hereditary Angioedema Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Asia-Pacific Hereditary Angioedema Sales Market Share by Region (2016-2026)
Figure 54. Asia-Pacific Hereditary Angioedema Sales Market Share by Application (2016-2026)
Figure 55. Asia-Pacific Hereditary Angioedema Sales Market Share by Region (2016-2026)
Figure 56. Asia-Pacific Hereditary Angioedema Revenue Market Share by Region (2016-2026)
Figure 57. China Hereditary Angioedema Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Japan Hereditary Angioedema Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Korea Hereditary Angioedema Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. India Hereditary Angioedema Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Southeast Asia Hereditary Angioedema Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Australia Hereditary Angioedema Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. South America Hereditary Angioedema Sales Market Share by Type (2016-2026)
Figure 64. South America Hereditary Angioedema Sales Market Share by Application (2016-2026)
Figure 65. South America Hereditary Angioedema Sales Market Share by Country (2016-2026)
Figure 66. South America Hereditary Angioedema Revenue Market Share by Country (2016-2026)
Figure 67. Brazil Hereditary Angioedema Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Argentina Hereditary Angioedema Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Middle East & Africa Hereditary Angioedema Sales Market Share by Type (2016-2026)
Figure 70. Middle East & Africa Hereditary Angioedema Sales Market Share by Application (2016-2026)
Figure 71. Middle East & Africa Hereditary Angioedema Sales Market Share by Country (2016-2026)
Figure 72. Middle East & Africa Hereditary Angioedema Revenue Market Share by Country (2016-2026)
Figure 73. Turkey Hereditary Angioedema Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Egypt Hereditary Angioedema Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Saudi Arabia Hereditary Angioedema Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. South Africa Hereditary Angioedema Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Sales Channel: Direct Channel vs Indirect Channel
Figure 78. Methodology
Figure 79. Research Process and Data Source